A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18F-MK-6240 PET
暂无分享,去创建一个
J. Seibyl | R. Gunn | M. Ichise | R. Comley | D. Wooten | P. Kuo | J. DuBois | C. Salinas | A. Whittington | Q. Guo | L. Martarello | Eddie C. Stage | Annie Racine | Jessica Collins | David Cheng | Lilly Porat
[1] G. Rabinovici,et al. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. , 2022, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] J. Morris,et al. Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[3] J. Gee,et al. Rates of longitudinal change in 18F‐flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[4] Julie Gonneaud,et al. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. , 2020, JAMA neurology.
[5] David T. Jones,et al. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.
[6] Sterling C. Johnson,et al. In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls , 2018, The Journal of Nuclear Medicine.
[7] H. Braak,et al. Top-Down Projections Direct the Gradual Progression of Alzheimer-Related Tau Pathology Throughout the Neocortex. , 2019, Advances in experimental medicine and biology.
[8] David T. Jones,et al. Joint associations of β-amyloidosis and cortical thickness with cognition , 2018, Neurobiology of Aging.
[9] Daniel R. Schonhaut,et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.
[10] Keith A. Johnson,et al. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global &bgr;-Amyloid Burden , 2017, JAMA neurology.
[11] Yiyun Huang,et al. PET Imaging for Early Detection of Alzheimer's Disease: From Pathologic to Physiologic Biomarkers. , 2017, PET clinics.
[12] O. Hansson,et al. Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks , 2017, Front. Neurosci..
[13] Gereon R Fink,et al. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.
[14] H. Braak,et al. Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. , 2016, Cold Spring Harbor perspectives in biology.
[15] Talakad G. Lohith,et al. Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.
[16] A. Joshi,et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.
[17] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.